[go: up one dir, main page]

MA31580B1 - Derives de bicyclolactames substitués - Google Patents

Derives de bicyclolactames substitués

Info

Publication number
MA31580B1
MA31580B1 MA32575A MA32575A MA31580B1 MA 31580 B1 MA31580 B1 MA 31580B1 MA 32575 A MA32575 A MA 32575A MA 32575 A MA32575 A MA 32575A MA 31580 B1 MA31580 B1 MA 31580B1
Authority
MA
Morocco
Prior art keywords
substituted
derivatives
bicyclolactam derivatives
substituted bicyclolactam
compositions
Prior art date
Application number
MA32575A
Other languages
English (en)
Inventor
Robert Lee Dow
Michael John Munchhof
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA31580B1 publication Critical patent/MA31580B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSÉS DE FORMULE (1), ET LEURS SELS PHARMACEUTIQUEMENT ACCEPTABLES, DANS LAQUELLE R1, R2, R3, R4, R5A, R5B, R5C, R5D, Q, A, Z, ET R7 SONT TELS QUE DÉCRITS DANS LA DESCRIPTION; LEURS COMPOSITIONS; ET LEURS UTILISATIONS.
MA32575A 2007-08-02 2010-02-02 Derives de bicyclolactames substitués MA31580B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95350707P 2007-08-02 2007-08-02

Publications (1)

Publication Number Publication Date
MA31580B1 true MA31580B1 (fr) 2010-08-02

Family

ID=39926534

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32575A MA31580B1 (fr) 2007-08-02 2010-02-02 Derives de bicyclolactames substitués

Country Status (34)

Country Link
US (2) US20090036425A1 (fr)
EP (1) EP2185567B1 (fr)
JP (1) JP4629808B2 (fr)
KR (1) KR20100032443A (fr)
CN (1) CN101772504A (fr)
AP (1) AP2010005163A0 (fr)
AR (1) AR067780A1 (fr)
AT (1) ATE502948T1 (fr)
AU (1) AU2008281545B2 (fr)
BR (1) BRPI0815067A2 (fr)
CA (1) CA2695291C (fr)
CL (1) CL2008002227A1 (fr)
CO (1) CO6251365A2 (fr)
CR (1) CR11223A (fr)
CY (1) CY1111628T1 (fr)
DE (1) DE602008005757D1 (fr)
DK (1) DK2185567T3 (fr)
DO (1) DOP2010000046A (fr)
EA (1) EA201000050A1 (fr)
EC (1) ECSP109932A (fr)
ES (1) ES2361716T3 (fr)
HN (1) HN2008001191A (fr)
HR (1) HRP20110335T1 (fr)
MA (1) MA31580B1 (fr)
PA (1) PA8791601A1 (fr)
PE (1) PE20090897A1 (fr)
PL (1) PL2185567T3 (fr)
PT (1) PT2185567E (fr)
SI (1) SI2185567T1 (fr)
TN (1) TN2010000053A1 (fr)
TW (1) TWI356059B (fr)
UA (1) UA94833C2 (fr)
WO (1) WO2009016462A2 (fr)
ZA (1) ZA201000255B (fr)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006064189A1 (fr) 2004-12-14 2006-06-22 Astrazeneca Ab Dérivés d'oxadiazole en tant qu'inhibiteurs de dgat
EP1966221A1 (fr) 2005-12-22 2008-09-10 AstraZeneca AB Pyrimido-[4,5-]-oxazines pour utilisation en tant qu'inhibiteurs de dgat
AU2007245059B2 (en) 2006-03-31 2011-07-28 Novartis Ag New compounds
EP2041100B1 (fr) 2006-05-30 2010-12-22 AstraZeneca AB Acides 5-phénylamino-1,3,4-oxadiazol-2-ylcarbonylamino-4-phénoxy-cyclohexane carboxyliques substitués en tant qu'inhibiteurs de l'acétyl coenzyme a diacylglycérol acyltransférase
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
NZ611323A (en) 2006-06-23 2014-10-31 Abbvie Bahamas Ltd Cyclopropyl amine derivatives as histamin h3 receptor modulators
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
TW201038580A (en) * 2009-02-02 2010-11-01 Pfizer 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
TW201040174A (en) * 2009-02-03 2010-11-16 Pfizer 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one derivatives
WO2010089686A1 (fr) * 2009-02-04 2010-08-12 Pfizer Inc. Dérivés de 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one
DK3366686T3 (da) 2009-03-20 2020-11-23 Metabasis Therapeutics Inc Inhibitorer af diacylglycerol-o-acyltransferase 1 (dgat-1) og anvendelser deraf
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
SI2547679T1 (sl) 2010-03-19 2015-12-31 Pfizer Inc. Derivati 2,3 dihidro-1H-inden-1-il-2,7-diazaspiro(3.6)nonana in njihova uporaba kot antagonisti ali inverzni agonisti grelinskega receptorja
WO2011121350A1 (fr) 2010-04-01 2011-10-06 Astrazeneca Ab Inhibiteurs de dgat1 à base de 4-amino-7,8-dihydropyrimido[5,4,f][1,4]oxazépin-5(6h)-one
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
HUE025078T2 (en) 2010-10-29 2016-01-28 Pfizer N1 / N2-lactam-acetyl-CoA carboxylase inhibitors
WO2012112364A1 (fr) * 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Dérivés de lactame en tant qu'inhibiteurs de dgat-1
WO2012122075A1 (fr) * 2011-03-08 2012-09-13 Merck Sharp & Dohme Corp. Dérivés de lactame en tant qu'inhibiteurs de dgat-1
MX348860B (es) 2011-04-22 2017-06-30 Pfizer Derivados de pirazoloespirocetona para usarse como inhibidores de acetil-coa carboxilasa.
KR20140033377A (ko) 2011-05-10 2014-03-18 길리애드 사이언시즈, 인코포레이티드 나트륨 채널 조절제로서의 융합된 헤테로시클릭 화합물
KR101919080B1 (ko) * 2011-05-20 2018-11-16 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 디아실글리세롤 아실트랜스퍼라제 억제제로서의 신규 화합물
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
NO3175985T3 (fr) 2011-07-01 2018-04-28
CA2841757A1 (fr) 2011-07-15 2013-01-24 Etzer Darout Modulateurs de gpr 119
BR112014000288A2 (pt) 2011-07-22 2017-01-10 Pfizer moduladores do receptor de glucagon de quinolinila
WO2013030713A1 (fr) 2011-08-31 2013-03-07 Pfizer Inc. Hexahydropyrano[3,4-d][1,3]thiazine-2-amines
WO2013055910A1 (fr) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles associés
WO2013068439A1 (fr) * 2011-11-09 2013-05-16 Intervet International B.V. Composés 4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazépine comme inhibiteurs de dgat1
CN103917529B (zh) 2011-11-11 2016-08-17 辉瑞大药厂 2-硫代嘧啶酮类
WO2013119040A1 (fr) 2012-02-07 2013-08-15 Kainos Medicine, Inc. Composés comme inhibiteurs de l'enzyme diacylglycérol o-acyltransférase de type 1
AP2014007953A0 (en) 2012-04-06 2014-09-30 Pfizer Diacylglycerol acyltransferase 2 inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
WO2013162298A1 (fr) * 2012-04-25 2013-10-31 한국화학연구원 Nouveaux dérivés de bêta-alanine, leurs sels pharmaceutiquement acceptables et composition pharmaceutique les comprenant en tant qu'ingrédient actif
WO2013164730A1 (fr) 2012-05-04 2013-11-07 Pfizer Inc. Composés d'hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitués par des hétérocycliques à titre d'inhibiteurs d'app, bace1 et bace2
CN104411690A (zh) 2012-06-20 2015-03-11 霍夫曼-拉罗奇有限公司 作为lpar拮抗剂的取代的吡唑化合物
EP2897964A1 (fr) 2012-09-20 2015-07-29 Pfizer Inc. Composés de hexahydropyrano [3,4-d][1,3]thiazin-2-amine substitués par alkyle
EP2903985A1 (fr) * 2012-10-03 2015-08-12 Advinus Therapeutics Limited Composés spirocycliques et leurs compositions et applications médicinales
WO2014074668A1 (fr) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulateurs de gpr119 et traitement de troubles associés à ceux-ci
US9796729B2 (en) 2012-11-23 2017-10-24 Glaxosmithkline Llc Compounds as diacylglycerol acyltransferase inhibitors
US20150322082A1 (en) * 2012-11-23 2015-11-12 Glaxosmithkline Llc Novel compounds as diacylglycerol acyltransferase inhibitors
CA2893256A1 (fr) 2012-12-11 2014-06-19 Pfizer Inc. Composes d'hexahydropyrano [3,4-d][1,3]thiazin-2-amine en tant qu'inhibiteurs de bace1
JP6162820B2 (ja) 2012-12-19 2017-07-12 ファイザー・インク 炭素環式および複素環式置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
WO2014125394A1 (fr) 2013-02-13 2014-08-21 Pfizer Inc. Composés hexahydropyrano [3,4-d][1,3] thiazin-2-amine substitués par un hétéroaryle
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
WO2014140241A1 (fr) * 2013-03-15 2014-09-18 Intervet International B.V. Dérivés de pyridine en tant qu'inhibiteurs de dgat-1
CN104418866B (zh) 2013-08-23 2018-10-16 青岛黄海制药有限责任公司 Dgat1抑制剂及其制备方法和用途
JP6348582B2 (ja) 2013-10-09 2018-06-27 ファイザー・インク プロスタグランジンｅｐ３受容体の拮抗薬
SI3119757T1 (en) 2014-03-17 2018-08-31 Pfizer Inc. Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
RS58597B1 (sr) 2014-04-04 2019-05-31 Pfizer Biciklično-spojena heteroaril ili aril jedinjenja i njihova upotreba kao irak4 inhibitora
CN106459088A (zh) 2014-04-10 2017-02-22 辉瑞公司 2‑氨基‑6‑甲基‑4，4a，5，6‑四氢吡喃并[3，4‑d][1，3]噻嗪‑8a(8H)‑基‑1，3‑噻唑‑4‑基酰胺
WO2016092413A1 (fr) 2014-12-10 2016-06-16 Pfizer Inc. Composés indoliques et indazoliques qui activent l'ampk
JP2017538769A (ja) 2014-12-22 2017-12-28 ファイザー・インク プロスタグランジンｅｐ３受容体の拮抗薬
MA42035A (fr) 2015-05-05 2018-03-14 Pfizer 2-thiopyrimidinones
CA2987179C (fr) 2015-05-29 2020-08-25 Pfizer Inc. Composes heterocycliques comme inhibiteurs de l'enzyme vanine-1
PL3310784T3 (pl) 2015-06-17 2021-03-08 Pfizer Inc. Związki tricykliczne i ich zastosowanie jako inhibitory fosfodiesterazy
WO2016203335A1 (fr) 2015-06-18 2016-12-22 Pfizer Inc. Nouvelles pyrido [2,3-b] pyrazinones utilisées en tant qu'inhibiteurs de bromodomaines de la famille bet
JP2018527337A (ja) 2015-08-13 2018-09-20 ファイザー・インク 二環式縮合ヘテロアリールまたはアリール化合物
ES2865199T3 (es) 2015-08-27 2021-10-15 Pfizer Compuestos de heteroarilo o arilo condensados bicíclicos como moduladores de IRAK4
WO2017037567A1 (fr) 2015-09-03 2017-03-09 Pfizer Inc. Régulateurs de la frataxine
JP2018531924A (ja) 2015-09-24 2018-11-01 ファイザー・インク テトラヒドロピラノ［３，４−ｄ］［１，３］オキサジン誘導体、およびｂａｃｅ阻害剤としてのその使用
BR112018003489A2 (pt) 2015-09-24 2018-09-25 Pfizer n-[2-(2-amino-6,6-dissubstituído-4,4a,5,6-tetra-hidropirano[3,4-d][1,3]tiazin-8a(8h)-il)-1,3-tiazol-4-il]amidas
WO2017051294A1 (fr) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(3-amino-2,5-diméthyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides utiles comme inhibiteurs de bace
DK3397631T3 (da) 2015-12-29 2021-05-25 Pfizer Substituerede 3-azabicyclo[3.1.0]hexaner som ketohexokinase-inhibitorer
AU2017296338A1 (en) 2016-07-14 2019-01-03 Pfizer Inc. Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
CN108164548B (zh) * 2016-12-07 2020-09-08 四川大学 嘧啶并吗啉衍生物及其制备方法和用途
WO2019133445A1 (fr) 2017-12-28 2019-07-04 Inception Ibd, Inc. Aminothiazoles utilisés en tant qu'inhibiteurs de vanin-1
US11254660B2 (en) 2018-08-31 2022-02-22 Pfizer Inc. Combinations for treatment of NASH/NAFLD and related diseases
WO2020102575A1 (fr) 2018-11-16 2020-05-22 Inception Ibd, Inc. Aminothiazoles hétérocycliques et leurs utilisations
EP3972596B1 (fr) 2019-05-20 2025-07-16 Pfizer Inc. Combinaisons comprenant du benzodioxol en tant qu'agonistes de glp-1r destinées à être utilisées dans le traitement de la nash/nafld et de maladies associées
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
WO2020261144A1 (fr) 2019-06-28 2020-12-30 Pfizer Inc. Dérivés de 5-(thiophén-2-yl) -1h-tétrazole utilisés en tant qu'inhibiteurs de bckdk utiles pour le traitement de diverses maladies
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
WO2021155841A1 (fr) 2020-02-07 2021-08-12 Gasherbrum Bio, Inc. Agonistes hétérocycliques de glp-1
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
WO2023026180A1 (fr) 2021-08-26 2023-03-02 Pfizer Inc. Forme amorphe de (s)-2-(5-((3-éthoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tétrahydrofuran-3-yl)pyrimidine-5-carboxamide
JP7704982B2 (ja) 2021-12-01 2025-07-08 ファイザー・インク 糖尿病、腎疾患、ｎａｓｈおよび心不全を処置するための分枝鎖アルファケト酸デヒドロゲナーゼキナーゼ阻害剤としての３－フェニル－１－ベンゾチオフェン－２－カルボン酸誘導体
EP4508047A1 (fr) 2022-04-14 2025-02-19 Gasherbrum Bio, Inc. Agonistes hétérocycliques de glp-1
WO2024075051A1 (fr) 2022-10-07 2024-04-11 Pfizer Inc. Inhibiteurs et/ou agents de dégradation de hsd17b13
WO2024118524A1 (fr) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Composés d'azaindole et leur utilisation en tant qu'inhibiteurs de phosphodiestérase
EP4634180A1 (fr) 2022-12-15 2025-10-22 Gasherbrum Bio, Inc. Sels et formes solides d'un composé ayant une activité agoniste de glp-1
CN120731201A (zh) 2022-12-16 2025-09-30 辉瑞公司 含3-氟-4-羟基苯甲酰胺的抑制剂和/或降解剂及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003201885B2 (en) * 2002-01-18 2007-08-30 Kyorin Pharmaceutical Co., Ltd. Fused bicyclic pyrimidine derivatives
AU2003293006A1 (en) * 2002-11-22 2004-06-18 Japan Tobacco Inc. Fused bicyclic nitrogen-containing heterocycles
AU2005209115A1 (en) * 2004-01-30 2005-08-11 Japan Tobacco Inc. Anorectic compounds
JP2006056881A (ja) * 2004-07-21 2006-03-02 Takeda Chem Ind Ltd 縮合環化合物
EP1966221A1 (fr) * 2005-12-22 2008-09-10 AstraZeneca AB Pyrimido-[4,5-]-oxazines pour utilisation en tant qu'inhibiteurs de dgat

Also Published As

Publication number Publication date
CY1111628T1 (el) 2015-10-07
AP2010005163A0 (en) 2010-02-28
JP2010535190A (ja) 2010-11-18
PE20090897A1 (es) 2009-08-06
TW200916471A (en) 2009-04-16
US20090137551A1 (en) 2009-05-28
PA8791601A1 (es) 2009-12-16
BRPI0815067A2 (pt) 2015-02-10
UA94833C2 (en) 2011-06-10
SI2185567T1 (sl) 2011-06-30
CL2008002227A1 (es) 2009-04-17
AU2008281545A1 (en) 2009-02-05
EA201000050A1 (ru) 2010-08-30
PL2185567T3 (pl) 2011-07-29
CA2695291C (fr) 2012-04-17
DK2185567T3 (da) 2011-05-16
AR067780A1 (es) 2009-10-21
US20090036425A1 (en) 2009-02-05
CO6251365A2 (es) 2011-02-21
KR20100032443A (ko) 2010-03-25
TN2010000053A1 (fr) 2011-09-26
US7718645B2 (en) 2010-05-18
ECSP109932A (es) 2010-03-31
CN101772504A (zh) 2010-07-07
CR11223A (es) 2010-02-04
CA2695291A1 (fr) 2009-02-05
EP2185567B1 (fr) 2011-03-23
JP4629808B2 (ja) 2011-02-09
WO2009016462A2 (fr) 2009-02-05
HN2008001191A (es) 2012-01-17
DOP2010000046A (es) 2010-03-31
PT2185567E (pt) 2011-05-27
WO2009016462A3 (fr) 2009-03-26
ATE502948T1 (de) 2011-04-15
DE602008005757D1 (de) 2011-05-05
TWI356059B (en) 2012-01-11
AU2008281545B2 (en) 2011-12-08
ES2361716T3 (es) 2011-06-21
ZA201000255B (en) 2011-03-30
HRP20110335T1 (hr) 2011-06-30
EP2185567A2 (fr) 2010-05-19

Similar Documents

Publication Publication Date Title
MA31580B1 (fr) Derives de bicyclolactames substitués
GT200600134A (es) Compuestos novedosos de derivados de aminosulfonilo
MA33384B1 (fr) Sulfonamides hétérocycliques, leurs utilisations et compositions pharmaceutiques les contenant
MA29909B1 (fr) Derives de pyridazine
GEP20094736B (en) Prodrugs of piperazine and substituted piperidine antiviral agents
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
MA32711B1 (fr) Pyrrolidine-2-carboxamides substitues
UY30274A1 (es) Derivados sustituidos de la n-(4-metil-1,3-tiazol-2-il)guanidina, formulaciones farmacéuticas conteniéndolo y aplicaciones
TN2010000052A1 (fr) Derives de pyrazole et leur utilisation comme inhibiteurs de raf
ECSP088549A (es) Nuevos derivados de pirrol fusionado
ECSP099755A (es) Derivados de pirrolopiridina y su uso como inhibidores de bace
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
MA30725B1 (fr) Administration d'inhibiteurs de la dipeptidyl peptidase
UY29927A1 (es) Derivados sustituidos de la 5-fenil-2-tioxo-imidazolin-4-ona y de la 5-fenil-2-amino-imidazolidin-4-ona y sus sales, composiciones y aplicaciones
MA35451B1 (fr) Dérivés de pyrrolopyrimidine et de purine
MA31433B1 (fr) Inhibiteurs de la p70 s6 kinase
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
EA200870217A1 (ru) 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
UY29919A1 (es) Derivados sustituidos de 3,4-dihidroisoquinolin-1-amino-trifluoroacetato, sus composiciones farmacéuticas y aplicaciones
AR065280A1 (es) Agentes antiparasitarios
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
MA29775B1 (fr) Derives de pyrazolone
MA32150B1 (fr) Inhibiteurs heterocycliques de la stearoyl-coa desaturase
MA31598B1 (fr) Composes antiviraux, compositions et leurs procedes d'utilisation
MA30821B1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes